

- **Name:** Sun Young Kim
- **Current Position & Affiliation:** Associate Professor, Asan Medical Center, University of Ulsan, College of Medicine
- **Country:** South Korea

• Educational Background:

FEB 2001	M.D., Seoul National University College of Medicine, Korea
FEB 2006	M.S., Seoul National University College of Medicine, Korea
FEB 2012	Ph.D., Seoul National University College of Medicine, Korea

• Professional Experience:

MAR 2001 - FEB 2002	Internship, Seoul National University Hospital, Seoul, Korea
MAR 2002 - FEB 2006	Resident, Dept. of Internal Medicine, Seoul National University Hospital, Seoul, Korea
MAR 2006 - FEB 2007	Fellow, Division of Hemato-Oncology, Seoul National University Hospital, Seoul, Korea
MAR 2007 - FEB 2008	Fellow, Center for Clinical Trials, National Cancer Center, Goyang, Korea
MAR 2008 - FEB 2016	Staff physician, Division of Hemato-Oncology, Center for Colorectal Cancer, National Cancer Center, Goyang, Korea
MAR 2016 – FEB 2019	Clinical Assistant Professor, Division of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
MAR 2019 – present	Associate Professor, Division of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

• Professional Organizations:

Member of Korean Medical Association
 Member of the Korean Association of Internal Medicine
 Member of Korean Cancer Study Group
 Member of Korean Association of Clinical Oncology
 Member of American Society of Clinical Oncology

• Main Scientific Publications:

1. Tak, E., M. Kim, Y. Cho, S. Choi, J. Kim, B. Han, H. D. Kim, C. S. Jang, J. E. Kim, Y. S. Hong, **S. Y. Kim** and T. W. Kim (2022). "Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance." *Oncol Rep* 47(1).
2. Hyung, J., E. J. Cho, J. Kim, J. H. Kim, J. E. Kim, Y. S. Hong, T. W. Kim, C. O. Sung and **S. Y. Kim** (2022). "Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response Among Patients with Microsatellite Instability–High Colon Cancer." *Cancer Res Treat* 2022.
3. **Kim, S. Y.**, J. S. Lee, J. Kang, S. Morita, Y. S. Park, J. Sakamoto, K. Muro, R. H. Xu and T. W. Kim (2021). "Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT)." *Oncologist* 26(6): e954-e962.
4. **Kim, S. Y.**, K. Kim, S. H. Cho, S.-M. Chun, E. Tak, Y. S. Hong, J. E. Kim and T. W. Kim (2021). "Longitudinal change of genetic variations in cetuximab-treated metastatic colorectal cancer." *Cancer Genetics* 258-259: 27-36.
5. **Kim, S. Y.** and T. W. Kim (2020). "Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer." *ESMO Open* 5(2).
6. Jho, H. J., E. J. Nam, I. W. Shin and **S. Y. Kim** (2019). "Changes of End of life Practices for Cancer Patients and Their Association with Hospice Palliative Care Referral over 2009-2014: A Single Institution Study." *Cancer Res Treat*.
7. Hong, Y. S., **S. Y. Kim**, J. S. Lee, B. H. Nam, K. P. Kim, J. E. Kim, Y. S. Park, J. O. Park, J. Y. Baek, T. Y. Kim, K. W. Lee, J. B. Ahn, S. B. Lim, C. S. Yu, J. C. Kim, S. H. Yun, J. H. Kim, J. H. Park, H. C. Park, K. H. Jung and T. W. Kim (2019). "Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial." *J Clin Oncol* 37(33): 3111-3123.
8. Cha, Y., **S. Y. Kim**, H. Y. Yeo, J. Y. Baek, M. K. Choi, K. H. Jung, S. M. Dong and H. J. Chang (2019). "Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer." *Neoplasia* 21(1): 146-155.

15th Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

9. Lee, S. W., H. J. Jho, J. Y. Baek, E. K. Shim, H. M. Kim, J. Y. Ku, E. J. Nam, Y. J. Chang, H. J. Choi and **S. Y. Kim** (2018). "Outpatient Palliative Care and Aggressiveness of End-of-Life Care in Patients with Metastatic Colorectal Cancer." *Am J Hosp Palliat Care* **35**(1): 166-172.
10. **Kim, S. Y.**, M. J. Yoon, Y. I. Park, M. J. Kim, B. H. Nam and S. R. Park (2018). "Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment." *Gastric Cancer* **21**(3): 453-463.